Recommendation...Men with hormone receptor–positive breast cancer who are candidates for adjuvant endocrine therapy but have a contraindication to tamoxifen may be offered gonadotropin-releasing hormone agonist/antagonist and an aromatase inhibitor (Type: formal consensus; Evidence quality: low; Strength of recommendation: moderate).